MedWatch

Coloplast expects organic growth of 7 percent next year

For the financial year 2021/2022, Coloplast is anticipating an organic growth of 7 percent in current exchange rates and an EBIT margin of 32 percent, it reports in connection with the release of its year-end results from the skewed 2020/21 financial year.

Photo: Coloplast / PR

Medtech company Coloplast is expecting to reach the same organic growth it landed on in the financial year that just ended for the next financial year of 2021/2022, it states in its year-end report from 2020/2021, which was released on Monday.

Coloplast is now estimating an organic growth of 7 percent in current exhange rates (CER) for the new financial year, after the organic growth in 2020/2021 likewise ended on 7 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs